Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orlistat 60 mg as Adjuvant Treatment of Obesity
NCT01755676Phase 3Completed
- Sponsor
- EMS
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Orlistat 60 mg with Placebo (2 arms). Primary endpoint: Efficacy of Orlistat 60 mg associated with diet and exercise in relation to placebo associated with diet and exercise in obesity treatment based on weight loss at 112 days. Started Sep 2016; status: completed.
02
Drugs
orlistat
03
Conditions
obesity
Beyond the preview
Go deeper on NCT01755676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01755676.